2012 ANNUAL REPORT ROAD TO A CURE

RESEARCH INVESTMENTS

PAVE THE WAY

ROAD TO A CUREROAD TO A CURE2 0 1 2 A N N U A L R E P O R T

2012 ANNUAL REPORT • 1

Randy Beranek President and CEO

Dan Farrington Chair, Board of Trustees

Dear Supporter,

This has been a year of incredible breakthroughs in psoriasis and psoriatic arthritis research. The National Psoriasis Foundation is proud to have played a leading role in supporting work toward solving the puzzle of psoriasis.

In fiscal year 2012, the Foundation invested $2.21 million in our research program, including grants and fellowships, our largest amount to date. We funded several studies that could improve the lives of people with psoriasis and psoriatic arthritis. In the past year, the Foundation has:

» Funded a study by cardiologist Nehal N. Mehta, M.D., that shows inflammation in skin and other organs and joints in people with psoriasis, suggesting a link between psoriasis to other serious diseases.

» Backed research by Nicole Ward, Ph.D., that shows psoriasis can cause cardiovascular disease and demonstrated that treating psoriasis can help reduce the risk of heart disease.

» Supported the work of Anne Bowcock, Ph.D., that identified the first gene directly linked to plaque psoriasis.

All told, the Foundation awarded 26 grants and fellowships in 2012 to researchers whose projects have the potential to improve treatments for people with psoriasis and psoriatic arthritis and, ultimately, lead to a cure. Our investment is intended to help promising researchers get their studies off the ground and eventually attract long-term funding. We have had success in reaching that goal. Both Drs. Mehta and Ward used the results from their Foundation-backed studies to apply for and receive funding from the National Institutes of Health, the largest source of medical research funding in the world.

In this report, you’ll learn more about promising studies backed by the Foundation that have the potential to make psoriasis treatments more affordable and accessible and help doctors diagnose psoriatic arthritis earlier.

Your generous contributions were essential to the progress made over the past year. Thanks to your support, the Foundation exceeded $8 million in total revenue, including a record $2.03 million in net revenue in 2012 through special events, such as the inaugural Commit to Cure Gala and the Walk to Cure Psoriasis. With your help, we can achieve our mission to find a cure for psoriasis and psoriatic arthritis and to eliminate their devastating effects.

Sincerely,

Randy Beranek Dan Farrington President and CEO Chair, Board of Trustees

EDITORIAL STAFFCatie Coman Vice President of Marketing and Communications

Tamara Miller Editor/Writer

Tina Rouhoff Creative Services Manager

Julianna Johnson Graphic Designer

2 • NATIONAL PSORIASIS FOUNDATION

1966

Classified ad placed in a Portland, Ore. newspaper to connect people affected by psoriasis

MILESTONESMILESTONES 1968National Psoriasis Foundation founded in Portland, Ore.

1970NPF sponsors the first National Institutes of Health psoriasis workshop for 105 scientists

FIVE-POINT ACTION PLAN

The mission of the National Psoriasis Foundation is to find a cure for psoriasis and psoriatic arthritis and to eliminate their devastating effects through research, advocacy and education.

THE FOUNDATION HAS A

FIVE-POINT ACTION PLAN TO FIND BETTER TREATMENTS AND A CURE:

1Fund the startup of promising new and innovative studies through our Discovery and Translational Grants

2Increase the number of scientists doing psoriatic disease research through our Medical Research Fellowship program

3Provide scientists with DNA samples through the National Psoriasis Victor Henschel BioBank, aiding their search for specific genes that cause psoriasis and psoriatic arthritis

4Work with federal policymakers to increase government investment in psoriatic disease research

5Promote patient involvement in research studies and clinical trials, vital to bringing safe and effective treatments to market


1974NPF successfully lobbies for FDA approval of methotrexate

1975National Psoriasis Foundation launches its research grant program

1975NPF secures the first federally-mandated funding for psoriasis research

1974NPF helps create the first NIH grant for psoriasis research, which was awarded to the University of Michigan

2012FOUNDATION HIGHLIGHTS

2012FOUNDATION HIGHLIGHTS

2.1 MILLION visits to psoriasis.org & TalkPsoriasis.org

200,000 Number of e-newsletter subscribers

15,506 Facebook fans, a 41-percent increase from 2011

4,796 Twitter followers, an 85-percent increase from 2011

26 Number of grants and fellowships awarded by the Psoriasis Foundation

5,822 Number of people who joined TalkPsoriasis in the last year

10,200 Number of TalkPsoriasis users, an almost 57-percent increase from 2011

1,076 Number of More than Skin Deep participants

3,857 Number of Psoriasis Foundation webinar viewers

MORE THAN2.1 MILLION Number of people served by the National Psoriasis Foundation

7.5 MILLION Number of people with psoriasis

30 PERCENTEstimated percentage of people with psoriasis who have psoriatic arthritis

FY2012 BY THE NUMBERS

2,622 Number of times Foundation staff responded to health, insurance, discrimi- nation and other information requests

5,000 Number of letters sent to the U.S. Congress by Foundation advocates

$2,035,017 Net amount raised through Walk to Cure Psoriasis and other special events

$8,985,621Donations, special events, and other revenue, largest amount in Foundation history

5,320 Number of times the National Psoriasis Foundation was referenced or contacted for news stories, including in the Huffington Post, Wall Street Journal, Women’s Health magazine, PBS and the New York Times

$2.21 MILLION Amount the Psoriasis Foundation invested in research, highest amount to date

165,000 Estimated number of readers of the Psoriasis Advance

225,000 Number of people with psoriatic disease who receive better insurance coverage and access to care as a direct result of Psoriasis Foundation advocacy efforts


1976NPF successfully lobbies the FDA to prevent removal of over-the-counter coal tar from market

1981NPF successfully lobbies the FDA for PUVA approval

1987NPF awards its first annual psoriasis research grants

1975NPF awards its first research fellowships to young scientists studying psoriatic diseases

The Road to a CureBegins with Basic Research



1994National Psoriasis Foundation Tissue Bank is established to study the genetic basis of psoriasis

1994NPF awards its first research grant for psoriatic arthritis

1998First biologic medications to treat psoriasis are introduced

1999NPF holds its first annual Residents Meeting to train young physicians how to treat psoriatic diseases




2003Three genes linked to psoriasis are found by NPF-supported researchers using data from the NPF Tissue Bank

2005National Psoriasis Foundation launches its advocacy department

2002Etanercept (Enbrel) is the first biologic approved by the FDA to treat psoriatic arthritis

SIGNS BEFORE SYMPTOMSOf the 7.5 million people living with psoriasis, an estimated 30 percent of them have psoriatic arthritis. A good portion of people with psoriatic arthritis do not have significant flares on the skin.

That’s just one of the reasons psoriatic arthritis can be difficult to diagnose.

“Psoriatic arthritis has such a varied presentation,” Ogdie said. “Every patient looks different.”

DISCOVERY GRANT RESEARCHER

DR. ALEXIS OGDIE

Imagine if you could find out you were becoming

seriously ill —before having any symptoms. Now

imagine if you could take medicine and lessen the

severity of the symptoms to come—or eliminate

them entirely.

That’s the idea behind the research of University

of Pennsylvania rheumatologist and researcher

Dr. Alexis Ogdie.

The National Psoriasis Foundation awarded Ogdie

the one-year, $50,000 A. Marilyn Sime Discovery

Grant to continue her study into whether whole-

body scans made with imaging technology can be

used to detect psoriatic arthritis before it causes pain

and swelling of the joints. The research gives hope to

the idea that psoriatic arthritis can be detected, and

treated, earlier and before significant joint damage.

DR. ALEXIS OGDIE

Illustration © veer.com/artist/bubaone


2005National Psoriasis Foundation holds its first annual Capitol Hill Day, bringing advocates to speak with Congress about psoriatic diseases

2007Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act (PPARCCA)—the first psoriasis and psoriatic arthritis legislation—is first introduced into Congress

2007Psoriasis is linked to increased risk of heart disease

2006National Psoriasis Victor Henschel BioBank is founded to study the roles of genes in psoriatic diseases

A. Marilyn Sime, Ph.D., R.N., has lived with psoriasis and psoriatic arthritis since her 20s. She also is a professor emerita at the University of Minnesota School of Nursing and spends much of her time teaching graduate students research methodology.

She recently combined her interests to provide $50,000 for the one-year National Psoriasis Foundation Discovery Grant awarded to Dr. Alexis

Unlike rheumatoid arthritis, there currently is no blood test to determine if a person has psoriatic arthritis. Doctors use a combination of ways to diagnose psoriatic arthritis: patient history, physical exam, X-rays, magnetic resonance imaging (MRI) and ultrasound.

Ogdie’s team will use Positron Emission Tomography/Computed Tomography, or PET/CT scans to look for a form of sugar, glucose, in the body, using the idea that inflammatory cells take up sugar to create inflammation.

Already, Ogdie’s team has found inflammation in the joints of psoriasis patients who have not yet experienced symptoms of psoriatic arthritis. That has the potential to improve patient outcomes.

“If you could diagnose the disease earlier, you can prevent the bad inflammation and joint deformities that occur in the disease,” Ogdie said.

RESEARCH BREAKTHROUGHSOgdie’s research builds on that of another Foundation-backed researcher and fellow University of Pennsylvania researcher, cardiologist Dr. Nehal N. Mehta. Mehta was the lead author of a study, also funded by a Discovery Grant, that created images showing inflammation in several organs of people with psoriasis. Studies showing the connection between psoriatic diseases and comorbidities, such as Type 2 diabetes, stroke and heart disease, have given momentum to psoriasis research.

“It’s great that there is growing interest in psoriasis,” Ogdie said. “Knowing more about subclinical diseases, such as inflammation with patients with psoriasis … helps us in identifying which treatments are working and how.”

The Foundation’s Discovery Grant was critical to Ogdie’s research, she said.

“This was absolutely necessary, because there was no other funding available at the time,” Ogdie said.

Ogdie, University of Pennsylvania rheumatologist and researcher.

Sime has been a generous donor for more than 20 years.

“As someone living with psoriasis and psoriatic arthritis, Sime has a unique perspective,” said Board Chairman Dan Farrington. “We are honored that she has chosen to invest in the Foundation’s work to find better treatments, and ultimately, a cure.”

A. MARILYN SIME DISCOVERY GRANTIll

ustr

atio

n by

Jul

iann

a Jo

hnso

n


2008Aetna improves its insurance plan for people with psoriasis based on recommendations from the National Psoriasis Foundation

MARCH

2009Grammy Award-winning artist LeAnn Rimes travels with the NPF to Capitol Hill to share her psoriasis story with Congress

JULY

2009LeAnn Rimes asks Congress to grant $1.5 million to the CDC for a psoriasis patient registry

2008Scientists at Washington University School of Medicine in St. Louis uncover 7 new DNA variations, or genetic links, involved in psoriasis

TRANSLATIONAL GRANT RESEARCHER

DR. SAM HWANG

Lotions and pills often aren’t enough to keep the

symptoms of moderate to severe psoriasis and psoriatic

arthritis at bay.

For many people with psoriatic diseases, the most

effective treatment comes from taking biologics—

a medicine derived from living cells cultured in a

laboratory. Right now, the only way to receive biologic

medicine is through infusions or needle syringes and let

it circulate throughout the body. That spells relief for

many, but not always: Biologics are expensive, require

regular doctor’s office visits and don’t work for everyone.DR. SAM HWANG

However, promising research led by Dr. Sam Hwang of the Medical College of Wisconsin could lead to more affordable and more accessible treatment in the future.

Funded by the two-year, $200,000 National Psoriasis Foundation Lutto Translational Grant, Hwang and his team of researchers hope to find small-molecule compounds that will block a protein produced by the body called CCR6, which has been linked to psoriasis inflammation. If successful, those small-molecule compounds – smaller than those used in biologics today – could be formulated into a less-expensive and easy-to-take cream, ointment or pill.Illustration © veer.com/artist/bubaone


DECEMBER

2009Congress approves $1.5 million for the first-ever psoriasis data collection at the CDC

SEPTEMBER 1

2010First DNA samples from the National Psoriasis Victor Henschel BioBank released for study

OCTOBER

2010New York becomes the first state to ban specialty tiering of prescription drug prices by insurance companies

APRIL

2011Psoriasis is associated with double the risk for metabolic syndrome—a cluster of conditions such as heart disease, high blood pressure and abdominal obesity

WHAT IS A BIOLOGIC?

Biologics are made from antibodies—very large proteins created by the human body to fight infection. Those antibodies help people with diseases like psoriasis and psoriatic arthritis by blocking certain cells or chemical messengers in the immune system. Most biologics used today block a chemical messenger called tumor necrosis factor-alpha, or TNF-alpha. There is too much TNF-alpha in the skin and joints of people with psoriasis and psoriatic arthritis. This leads to the rapid growth of skin cells typical of psoriasis, or to the joint inflammation characterized by stiffness, pain, warmth and redness seen in psoriatic arthritis. A reduction in TNF-alpha, a critical regulator of inflammation, stops the inflammatory cycle of psoriasis and psoriatic arthritis.

Because antibodies are so large, they have to be injected or infused into the body—the medicine literally is too large to put in a pill or lotion. A typical biologic costs a minimum of about $2,000 per month, before insurance.

THE SCIENCE OF PSORIASISHwang’s research team has been studying a family of proteins called chemokine receptors, which move human cells from one place to another. The team discovered that mice lacking the chemokine receptor CCR6 do not develop the skin inflammation in psoriasis. The team also discovered that blocking another chemokine, CCL20, prevented the development of psoriasis.

Hwang’s team is using the Translational Grant to search for molecules that can block CCR6 and CCL20. By using sophisticated computer systems, they hope to find small molecules that a pharmaceutical company can formulate into a cream, ointment or pill that would prevent mild to moderate psoriasis flares.

So far, the team is off to a good start.

“Within three months of starting, we’ve already identified one compound,” Hwang said. “I would fully expect to identify three to five lead compounds in the next one or two years.”

FROM THE LAB TO THE BEDSIDEHwang has long had an interest in the role chemokine receptors play in autoimmune diseases.

“Being in dermatology and seeing psoriasis patients all the time, it really struck me that this kind of data could lead to better therapy for psoriasis,” Hwang said.

His team’s research could be used to help treat other autoimmune diseases, such as rheumatoid arthritis.

The Foundation’s support has been critical to furthering Hwang’s research. It’s also helped him realize the needs of people with psoriasis and psoriatic arthritis. In his opinion, the future of psoriatic disease research looks very bright.

“There’s going to be a lot (of research) in the next five to six years that will make treatment more effective, cheaper and easier on the patient,” Hwang said.

ABOUT THE LUTTO BEQUEST$2 MILLION—largest in Foundation history

Larry Lutto struggled with psoriasis for much of his life. After he died at age 32, his parents wanted to help find better treatments and a cure so that others would not suffer as their son had. Seymour (Sy) and Rebecca Lutto named the National Psoriasis Foundation as a beneficiary in their living trust agreements. Both died within months of each other in 2011.

“In honor of their very generous contribution, the Foundation established the Lutto Translational Grant to fund research focused on rapidly translating scientific discoveries that will clearly benefit people with psoriasis and psoriatic arthritis,” said Board Chairman Dan Farrington.

Sy Lutto was a copy editor for The New York Times for 47 years. He is remembered for his humor, kind heart and modesty. Rebecca Lutto worked as a librarian and freelance writer, and earned some attention for a letter to the editor to The New York Times that included the oft-quoted statement, “Sometimes inefficiency is the price we pay for democracy.”

On behalf of all families who struggle with psoriasis and psoriatic arthritis, we will honor their legacy by continuing to invest in research that will one day pay off with a cure.


FEBRUARY

2012Premera Blue Cross improves its insurance plan for people with psoriasis based on recommendations from the National Psoriasis Foundation

OCTOBER 12

2011NPF research reveals nearly one in four people with psoriasis may have undiagnosed psoriatic arthritis

AUGUST

2011Capital Blue Cross improves its insurance plan for people with psoriasis based on recommendations from the National Psoriasis Foundation

MAY

2011Obesity in childhood found to significantly increase risk for psoriasis

Mark G. Lebwohl, M.D.ChairNew York, N.Y.

Lakeshi M. Aldredge, M.S.N., R.N., A.N.P.-B.C.

Portland, Ore.

Jerry Bagel, M.D.East Windsor, N.J.

Andrew Blauvelt, M.D.Portland, Ore.

Erin Boh, M.D., Ph.D.Covington, La.

Kristina Callis Duffin, M.D.Salt Lake City, Utah

Jeffrey Crowley, M.D.Los Angeles, Calif.

Lawrence Eichenfield, M.D.San Diego, Calif.

Alice Gottlieb, M.D., Ph.D.Boston, Mass.

Sylvia Hsu, M.D.Houston, Texas

Elaine Husni, M.D., M.P.H.Cleveland, Ohio

Abby A. Jacobson, M.S., P.A.-C

Lancaster, Pa.

Arthur Kavanaugh, M.D.La Jolla, Calif.

Gerald G. Krueger, M.D.Chairman EmeritusSalt Lake City, Utah

Abrar Qureshi, M.D., M.P.H.

Boston, Mass.

Christopher Ritchlin, M.D.Rochester, N.Y.

Linda Stein Gold, M.D.West Bloomfield, Mich.

Stephen Stone, M.D.Springfield, Ill.

Abby Van Vorhees, M.D.Philadelphia, Pa.

Jeffrey Weinberg, M.D.New York, N.Y.

Gerald D. Weinstein, M.D.Chairman EmeritusIrvine, Calif.

Stefan Weiss, M.D.Boca Raton, Fla.

Paul Yamauchi, M.D., Ph.D.Encino, Calif.

VOLUNTEER MEDICAL BOARD VOLUNTEER BOARD OF TRUSTEES Daniel FarringtonChairBethesda, Md.

Krista KelloggChair-ElectMiami, Fla.

Mark S. LillieVice-ChairChicago, Ill.

Eric KimbleSecretarySudbury, Mass.

Chip NewtonTreasurerSt. Petersburg, Fla.

Steve BishkoffOakhurst, N.J.

Colby Evans, M.D.Austin, Texas

Holly Fields KrafsurEl Paso, Texas

Kathleen L. GallantPittsburgh, Pa.

Lawrence Green, M.D.Rockville, Md.

Sarah Kurts, PA-CDenver, Colo.

Michael LaubNew York, N.Y.

Mark G. Lebwohl, M.D.New York, N.Y.

Pete ReddingReno, Nev. and

Phoenix, Ariz.

Terri TheisenAtlanta, Ga.

ex officioRichard SeidenImmediate Past ChairLos Angeles, Calif.

TREASURER’S LETTER

On behalf of the National Psoriasis Foundation Board of Trustees, I want to extend my deep gratitude to you, our donors. For the 2012 fiscal year, we received revenue of $8.9 million in gifts, pledges

and other support, an increase of 25 percent over the prior year. Your support helps to advance our mission to find a cure for psoriasis and psoriatic arthritis and to eliminate their devastating effects through research, advocacy and education.

We are continuing our focus on finding a cure for psoriasis and psoriatic arthritis and to increase our spending on research activities. During the fiscal year we awarded 15 new research grants totaling $1,397,320 and continued our Medical Dermatology Fellowship Program by funding twelve fellowship grants totaling $464,500. We continue to build the BioBank to further the study of psoriasis genetics. We also held our first Commit to Cure Gala which grossed $1 million to further research awards.

In its sixth year, our National Psoriasis Walk to Cure program raised $1,336,000. We are thankful to the many individuals and corporate sponsors who are helping to make this program increasingly successful.

During this fiscal year we committed over $6.1 million, or 80 cents of every dollar spent, to programs which advance the mission of the Foundation. Our balance sheet remains strong with $7.4 million in assets. We are committed to being fiscally responsible so that we can continue our mission during tough economic times.

Thank you for your generosity.

Sincerely,

Chip Newton


MARCH

2012Study finds that treating psoriasis with anti-TNF agents may reduce heart attack risk

APRIL

2012NPF-funded researcher receives a $7 million award from the NIH to study connection between psoriasis and heart disease

APRIL

2012Scientists use DNA from the National Psoriasis Victor Henschel BioBank to identify the first gene linked to plaque psoriasis

$2,035,017 Net special events revenue

$1,320,813 Individual contributions $2,587,162

Corporate contributions, Foundation contributions and sponsorships

$2,102,585 Legacies and bequests

$940,044 Fees, advertising and other

TOTAL REVENUE, GAINS AND OTHER SUPPORT $8,985,621 INCREASE IN NET ASSETS $1,309,785

STATEMENT OF ACTIVITIESSTATEMENT OF ACTIVITIES

YEAR ENDED JUNE 30, 2012

LIABILITIES

$348,291 Accounts payable and accrued liabilities

$19,370 Deferred revenue TOTAL LIABILITIES $367,661

NET ASSETS

$5,223,157 Unrestricted

$1,862,633 Temporarily restricted

TOTAL NET ASSETS $7,085,790

TOTAL LIABILITIES & NET ASSETS $7,453,451

14% Fund raising

17% Professional education and patient services

12%Advocacy and

governmentrelations

29%Research 23%

Public education

5%Management

and general

EXPENSES

$2,208,929 Research

$842,543 Advocacy and government relations

$784,166 Patient services

$1,790,540 Public education

$535,392 Professional education

$1,109,673 Fundraising

$404,593 Management and general

TOTAL EXPENSES $7,675,836

ASSETS

$6,128,440 Investments, cash & cash equivalents

$548,214 Pledges receivable-net

$420,400 Legacies and bequests receivable

$183,620 Other assets

$172,777 Accounts receivable

TOTAL ASSETS $7,453,451

REVENUE, GAINS AND OTHER SUPPORT

A complete copy of our audited financial statments is available on our website at www.psoriasis.org.

STATEMENT OF FINANCIAL POSITIONSTATEMENT OF FINANCIAL POSITION


MAY 15

2012National Psoriasis Foundation awards more than $2.21 million in grants and fellowships to 26 scientists studying psoriatic diseases

JUNE

2012Psoriasis linked to independent risk for type 2 diabetes

JULY

2012Massachusetts passes legislation enabling access to patient assistance programs

MAY

2012NPF-supported study identifies how psoriasis and heart disease are connected, shows treating psoriasis reduces cardiovascular risk

JULY 1, 2011–JUNE 30, 2012 CORPORATE PARTNERS AND SPONSORS

JULY 1, 2011–JUNE 30, 2012 CORPORATE PARTNERS AND SPONSORSThank you to the corporations and

organizations that donated their time,

funds and support to the National Psoriasis

Foundation. Through their contributions,

we are able to advance our mission to find a

cure for psoriasis and psoriatic arthritis, as

well as provide information and support to

those coping with the disease.

Be Joint Smart: In its second year, this coalition of the Arthritis Foundation and National Psoriasis Foundation continued to raise awareness about psoriatic arthritis and expanded to provide free education seminars for people with psoriatic arthritis on disease management, treatment and research. This program is made possible by funding from Amgen Pfizer.

PROGRAMS FUNDED BY OUR CORPORATE PARTNERS AND SPONSORS INCLUDE:

Medical Education: Caring for psoriasis requires familiarity with many different treatment regimens, knowledge of the latest research and a deep understanding that the chronic nature of psoriasis necessitates consistent and long-term care. The National Psoriasis Foundation continued hosting its two annual medical education programs, the Residents Meeting and Physician Assistants Psoriasis Summit, to link psoriasis and psoriatic arthritis experts with dermatologists and allied health professionals. Residents Meeting was made possible by funding from Abbott Laboratories, Amgen Pfizer, Beiersdorf, Inc., Daavlin and Galderma. Physician Assistants Psoriasis Summit was made possible by funding from Abbott Laboratories, Amgen Pfizer, Daavlin, Galderma and Janssen BioTech, Inc.

Medical Research Fellowships: Today, there is a shortage of researchers with in-depth expertise on psoriasis and psoriatic arthritis. The National Psoriasis Foundation Medical Research Fellowship program seeks to increase the number of scientists focused on studying and treating psoriasis and psoriatic arthritis by encouraging young scientists to become physician researchers and dedicate their careers to psoriatic diseases. The National Psoriasis Foundation Research Fellowships are made possible by a grant from Amgen.

More Than Skin Deep: More than 1,000 people with psoriasis and psoriatic arthritis, their family members and caregivers attended 22 free education seminars held by the National Psoriasis Foundation across the U.S. Participants had the opportunity to learn more about how to control their disease from some of the best health care providers in the country. More Than Skin Deep features a leading dermatologist and rheumatologist to discuss symptoms, diagnosis, treatment and management options, as well as the latest research advances toward a cure. These seminars were made possible by funding from Abbott Laboratories, Amgen Pfizer, Beiersdorf, Inc., Janssen BioTech, Inc., Galderma, Neutrogena and Novartis Pharmaceuticals.


SUPPORT FROM INDIVIDUALS, FOUNDATIONS AND COMPANIES

BEVERLY FOSTER HALPRIN SOCIETYNamed to honor the founder of the National Psoriasis Foundation

$75,000 OR MORE Michael and Carol Laub

$10,000 TO $24,999 Anonymous (2)

Susan Bershad, M.D.

Robert and Lauren Fales

Daniel and Rebecca Farrington

Steven Feldman, M.D., Ph.D. and Leora Henkin

Millie Fleskes

C. M. Garver

Donald and Lesley Grilli

Judy and Stanley Katz

The Katz Family Foundation

Virginia Morris Kincaid Charitable Trust

Jacob Levitt, M.D.

SUPPORT FROM INDIVIDUALS, FOUNDATIONS AND COMPANIES JULY 1, 2011–JUNE 30, 2012

$50,000 TO $74,999 Michael Graff and Carol Ostrow

A. Marilyn Sime, Ph.D., R.N.

RICHARD COFFMAN CIRCLENamed to honor the first chairman of the Psoriasis Foundation Board of Trustees

$25,000 TO $49,999 Jodi and Bill Felton

Neal and Barbara Henschel and Family

Mark G. Lebwohl, M.D.

Edward Lewis and Achara Pinpanna

Chip Newton and Liz Smith

CHAMPIONS

Mark and Celine Lillie

The Edward A. & Catherine L. Lozick Foundation

Tom and Laurie Markham

National Society for Cutaneous Medicine

Owens & Minor

Chester and Jacqueline Paulson

Florence Petrlik

Randi Rahm

Steven Rand and Nancy Wender

Peter and Lorelei Redding

Victoria W. Sack

Richard and Ellen Seiden

Alan and Bari Shaffran

Sun Capital Partners Foundation

Terri Theisen

University of Pennsylvania

The Webb Foundation

Michael and Melissa Weinbaum & The Attilio & Beverly Petrocelli Foundation

Dale and Karen White

Seth and Deb Wohlberg

Carol A. Yermal

$1 MILLION +

$500,000-$999,999

$250,000-$499,999

$100,000-$249,999

$25,000-$49,999 Valeant Pharmaceuticals

$10,000-$24,999 Beiersdorf, Inc.Celgene CorporationDaavlinFougera PharmaceuticalsNeutrogenaNovartis Pharmaceuticals

Pfizer, Inc.PharmaDermPhotoMedexRanbaxy Pharmaceuticals


MULTI-YEAR PLEDGES These donors have made long-term commitments to provide essential support for Foundation programs.

$1 MILLION Neal and Barbara Henschel

and family for the National Psoriasis Victor Henschel BioBank

$250,000 TO $499,999 Edward Lewis and Achara

Pinpanna

$50,000 TO $99,999 Bill and Jodi Felton

Dale and Karen White

$25,000 TO $49,999 Randy Beranek


$10,000 TO $24,999 Bill Cardamon and

Alicia Wright

Benjamin and Janice Isenberg

Krista Kellogg

Eric W. Kimble

BENEFACTORS $5,000 TO $9,999 Altman Dermatology

Associates

Aventura Mall Marketing Fund

Jerry Bagel, M.D.

Fabio Cuiabano Barbosa, M.D.

Randy Beranek

Frederic Bloch

Erin E. Boh, M.D., Ph.D.

Stan Burnstein

Sanford P. & Irene Burnstein Foundation

Corey Cardine

Russell, Judith, Cecily and Edward Carson

Case Western Reserve University

Jennifer Clay Cather, M.D.

Joseph and Elizabeth Chan

James Q. Del Rosso, D.O.

Dermatology Nurses Association

Drinker Biddle & Reath

Fisher Brothers Foundation

Dick and Meryl Friedman

Honor N. Fullerton, M.D. and David Stone

Irwin and Joan Geduld

Jeff and Lisa Henschel

Infinite Healthcare Partners

Irish Network San Francisco


Jewish Community Foundation

Michael J. John

Krista Kellogg

Eric W. Kimble

Leon Kircik, M.D.

Kirkland & Ellis Foundation

John Y. M. Koo, M.D.

Krafsur Family

Gerald G. Krueger, M.D.

Levitt Research Foundation

Medicis, The Dermatology Company

Alan Menter, M.D. and Pam Menter

Microsoft Corporation

Mark Oberman and Judith Eisenberg

Organization of Teratology Information Specialists

David Michael Pariser, M.D.

Phoebe Rich, M.D.

Marc & Carolyn Rowan Family Foundation

James A. Schamus

Lutz Schlicht

Schwab Charitable Fund

Society of Dermatology Physician Assistants

Stanford Dermatology

Linda Stein Gold, M.D.

Jack and Alice Styza

Taro Pharmaceuticals

Bruce Thiers, M.D.

Christina W. Tom

University of Michigan

Eugene J. Van Scott, M.D.

Abby S. Van Voorhees, M.D.

Walton Family Foundation

Byron Webb

Fred and Joan Weisman

Stefan Weiss, M.D.

Mark and Blanche Wine

Paul S. Yamauchi, M.D., Ph.D.

GUARANTORS $1,000 TO $4,999 Acorn Hill Foundation

Adobe Systems Incorporated

Advanced Care Scripts

Advanced Dermatology and Skin Cancer Center

Kent Aftergut, M.D.

Douglas Altchek, M.D.

American Century Investments

Nancy J. Anderson, M.D.

Dr. David W. Andrews

Anonymous (8)

Humberto C. Antunes

Ashish Anvekar

Rob Arango and The Plaza

Marc Arginteanu, M.D. and Ronit Arginteanu

Arlington Center for Dermatology

Anthony M. Armada, M.D.

Veronica Arnstein

Ashland Foundation

Louis and Susan Axelrod

Bank of America Charitable Gift Fund

Baptist Health South Florida

Tom and Ellen Barton

Joe and Nelda Beaud

Vincent Peter Beltrani, Jr., M.D.

Sonia Bender

Paula and Jordan Bergstein

Brian Berman, M.D., Ph.D.

J. Raymond Bernat, M.D.

Michael Bernhardt, M.D.

Neal Bhatia, M.D.

Jeffrey Biegelsen

The Biegelsen Foundation

Joseph B. Bikowski, M.D.

Steven and Tracy Bishkoff

Bonne, Bridges, Mueller, O'Keefe & Nichols

Richard K. Bowman

BPM Northwest

David H. Brockway

Eileen Brooks

R. Steven Brooks

Suzanne Bruce, M.D.

Jean R. Bruder

Mary Ruth Buchness, M.D.

Build-A-Bear-Workshop Hugs Foundation

Marian C. Burke

Jeffrey P. Callen, M.D.

Kristina Callis Duffin, M.D.

Bill Cardamon and Alicia Wright

Caremark RX

Patrick Carney, M.D.

Cary Dermatology Center

Michael and Carey Cavaliere

Roger I. Ceilley, M.D.

Brad and Judy Chase

Yoo Sang Choi

Michael Cisewski

Mary R. Clarbour

Cleveland Clinic Foundation

CNA Insurance Companies

Clay Cockerell, M.D. & Coquerel Family Wine Estates

Russell W. Cohen, M.D.

Steven R. Cohen, M.D., M.P.H.

Myron and Nancy Cohn

Colorado Dermatologic Society

Colorado Society of Dermatology Professionals

Colorado Springs Dermatology Clinic

Catie Coman and Scot Robinson

Meredith Conte

The James Cook Family

Kimberly and Robert Coretz

CPS 5

Jeffrey Crowley, M.D. and Sarah Crowley

Daavlin

Theodore Daly, M.D.

Thomas B. Daniels

Ronn and Nicole Davids

Robert Day, Ph.D. and Flora Day

Vincent A. Deleo, M.D.

Dermatology & Aesthetics of Wicker Park

Dermatology and Laser Institute of Colorado

Dermatology Associates of Morris

Diplomat Specialty Pharmacy

Paul and Ivy Dodwell

Amit Doshi

Terrance A. Doyle

Joseph S. Eastern, M.D.

Elorac

Colby C. Evans, M.D.

The Roy Gene & Pamela Evans Foundation

Evince Communications

Fahringer Foundation

Carrie and Steven Falkner

Patrick R. Feehan, M.D.

Edward Feigeles

Neil A. Fenske, M.D.

Adolfo Fernandez-Obregon, M.D.

Mathew Edward Saul Firman

Mark and Tara Flint

Ted Floor

Foley & Lardner

Form Analysis

Ellen H. Frankel, M.D.

Mark H. Fritze

GEICO Philanthropic Foundation

Leonard Genet

Robert and Adrienne Ginsberg

Dafna Gladman, M.D.

Brad P. Glick, D.O.

Gold & Rosenblatt

Henry L. Goldberg

The Goldfein Family Foundation

Gail Goldman, M.D.

Norman Goldstein, M.D.

Arlene & Arnold Goldstein Family Foundation

Amy Goleno

Michael D. Good

Good Works Health Inc.

Google Gift Matching Program

Alice Bendix Gottlieb, M.D., Ph.D.

Richard D. Granstein, M.D.

Lawrence Green, M.D. and Allison Green

Robert G. Greenberg, M.D.

Stephanie E. Grobaski

Kenneth A. Grossman, M.D.

Wolfgang Guenther, M.D. and Lyn Guenther

Paula H. Gwosdz

H&R Block

Charles L. G. Halasz, M.D.

Barry Hartzberg

David and Wendy Hashmall

Steven N. Hecht

Andrew and Nancy Henschel

Warren R. Heymann, M.D.

Margaret Hiler

Robert J. Hiler Family Foundation

Holy Family School

Francis W. Iacobellis, M.D.

Innocutis Holdings

Ernest Isenstadt

Ronen Israel

Brett Janecek

Peter J. Jenkin, M.D.

Brian Johnson

Dorothy Judevine

RECOGNITION OF GIFTS MADE JULY 1, 2011THROUGH JUNE 30, 2012


The National Psoriasis Foundation hosted its inaugural Commit to Cure Gala on June 7, 2012, which honored Dr. Mark Lebwohl, chairman of the Psoriasis Foundation Medical Board and a longtime leader in the organization.

More than 400 people gathered in the Grand Ballroom of New York’s Plaza Hotel. The event raised $1 million for the Dr. Mark G. Lebwohl Medical Dermatology Fellowship Awards to encourage early-career dermatologists to pursue psoriasis and psoriatic arthritis research. Students who have completed a three-year dermatology residency program or at least one year of a four-year program

that includes a research year will be eligible for a fellowship grant. Applicants must devote at least 75 percent of their effort to psoriatic disease research and their mentors must have an academic appointment in a dermatology program.

Dr. Lebwohl is highly respected around the world for his contributions to psoriasis research and patient care. He has served as the Psoriasis Foundation’s Medical Board chair for more than a decade and has encouraged young researchers to pursue psoriasis research throughout his career. Dr. Lebwohl is noted for his advocacy for patients and his contributions to the Foundation.

Thank you to the top Commit to Cure Gala Corporate Sponsors: Abbott Laboratories, Amgen Pfizer, Beiersdorf, Inc., Celgene Corporation, Fougera Pharmaceuticals, Galderma, Janssen BioTech, Inc., Leo Pharma, Inc., Lilly USA, LLC, Medicis Pharmaceuticals, PharmaDerm, PhotoMedex, Ranbaxy Pharmaceuticals, Taro Pharmaceuticals and Valeant Pharmaceuticals.

Robert E. Kalb, M.D.

"Lab Rat"

Kansas City Dermatology

Michael and Jacqueline Katz

Susan E. Katz, M.D.

The Katz Family Foundation

Craig Kauffman

Jacquelyn C. Keaveney

Alexandra B. Kimball, M.D., M.P.H.

Virginia Morris Kincaid Charitable Trust

William and Frances Klein

Scott and Patricia Klevenhagen

Kohl's

Neil Korman, M.D., Ph.D.

Michael Kraley

Indira Rao Krishnarao, M.D.

Wesley Kroger

Caren Krumerman

Kristine Kucera, PA-C, MPAS, DHS

Sarah A. Kurts, PA-C

Priscilla and Richard Kurz

Kathleen M. LaCroix

Michael and Jill Lamoretti

SaraLee and Barry Larner

Craig and Sharon Larson

Andrew and Lori Laub

Robyn and Marc Leach

Lerner Medical Devices

Ross S. Levy, M.D.

Wilson J. Liao, M.D.

Leo Liebowitz

The Liebowitz Foundation

Clive M. Liu, M.D.

Brenda Lockhart

Virginia P. Louloudes

Patricia and Daniel Luck

Marvin and Kristina Lustiger

Thomas G. MacCracken

Mark and Jaclyn Marinovich

Orit Markowitz, M.D.

Mavena Derma Centers

Emanual Maverakis, M.D.

Penny E. McConnell

Thomas S. McCormick, Ph.D.

David G. McIntee

Robert and Valerie McLean

Brian McMaster

McMaster Family Foundation

Philip J. Mease, M.D.

M. J. Mecklenburg

Medimetriks Pharmaceuticals

Andrew Mitchell, M.D.

David and Sheila Mitchell

Scott Morgan

Warwick L. Morison, M.D.

Manuel R. Morman, M.D., Ph.D.

Mount Kisco Medical Group

Mount Sinai School of Medicine Department of Dermatology

Mushatts

Ruth Mutch

National Biological Corporation

NeoStrata Company

Emil Neroda

New York Life Insurance

Newport Beachside Resort

Norfolk Southern Corp Good Government Fund

Don and Rema Norton

Edith J. Oberman

Robert H. Oleksyn

Oregon Health & Science University

Karen and Mark Oslund

Ed and Laura Owens

Pacific Marketing & Publishing

Etahn Cohen & Amy Paller Cohen

Roberta J. Palmer

Palo Alto Medical Foundation

Robert J. Pariser, M.D.

Erick Paulson

Linda and Michael Picciallo

Terilynn M. Pinkley

Pittsburgh Academy of Dermatology

Ann Feder-Pomerantz

Robert B. Posnick, M.D.

Ken Preston

Paul H. Prigge

Qualcomm Incorporated

Abrar A. Qureshi, M.D.

Bruce and Mary Rabiner

Mike and Hulda Refermat

Valerie Richards, Ph.D.

Richards & Richards

Terrence J. Riley

Christopher Ritchlin, M.D.

Rite Care Pharmacy Specialty & Compounding

Norman and Bettina Roberts Foundation

Andrew D. Robertson, Ph.D. & Sue M. Travis, Ph.D.

Rochdale Investment Management

Claran Roche

Rogerio F. Rojas

Gerry Rosenberg and Cheryl Wisenfeld Rosenberg

Randi B. Rosenblatt

Matthew Ross

George R. Russell, M.D.

Neil Sadick, M.D.

Alan and Joan Safir

Marc and Frances Samit

San Francisco Salt Co.

Sidney and Betsy Savelle

Richard and Wendy Schimel

Pamela B. Schultz

Jacci Seskin

Richard Sharpstein

Sue and Robert Shoenberg

Allen Shunk

Anne K. Silver

James S. Simpson

Howard L. Sofen, M.D.

Tracy F. Stein

Dorothy S. Stimpson

Stephen P. Stone, M.D.

Stout Industries Charitable Foundation

Elizabeth and William Struve

Sunflower Dermatology & Day Spa

Sussman Shank

Dina Tarro

Amy Forman Taub, M.D.

Craig F. Teller, M.D.

Therapeutics Clinical Research

TKL Research

Total Life Care Pharmacy

James E. Turner, M.D., Ph.D.

Toni and James Turner

Stephen K. Tyring, M.D., Ph.D.

US Bank

Allison Vidimos, M.D.

Vrishali Wagle

Walgreens Specialty Pharmacy

Wallack Management Co.

Jacque Waller

Dawn and Steven Watts

Robert M. Weekley

Theodore & Renee Weiler Foundation

Jeffrey M. Weinberg

Allison and Scott Weiss

Jonathan S. Weiss, M.D.

Roger K. West

Harry M. Wheeler

William and Barbara Whittaker

Chris Williams

John S. Wilson

Windsor Dermatology

Johnnie Woodson, M.D.

World One Research

Edward Wright

George Wundsam

Joseph and Sylvia Yasgur

Elizabeth A. Young

Melodie Smith Young, A.R.N.P.

Evelyn Zafran

Michael Zanolli, M.D.

Rolland Fritz Zeck

Photo by D&L Photography, Linda Pedersen/David Kenny


CHARITABLE GIFT ANNUITY


A special thanks to longtime supporters and Legacy Society members who, in FY2012, established the Foundation’s first Charitable Gift Annuity.

The National Psoriasis Foundation honors the memory of those

who generously planned for estate gifts received in fiscal year 2012.

Members have planned for future support by naming the National

Psoriasis Foundation as beneficiary in their will, trust, insurance

policy, retirement fund, charitable gift annuity or other estate plans.

Sandra Allison

Jack and Patricia Allweiss

Alexis M. Anderson

Anonymous (14)

Dot Aumann

Elsa Aybar

Corky L. Balzac

Robert and Cathleen Becker

George and Mary Bell

James P. Bennett, Ph.D.

Jeffrey B. Berman

Richard I. Besser

Frank M. Beveridge

Mary Kay Boylan

Robert L. Brooks

Richard Brotherston

LaVerne Beall Burhans

Mary B. Burrows

Laurie Anne Carlson

James Carolan

Howard and Lori Chang

Helene and Jerry Cotter

Enid L. Crook

Robert L. Crooks and Sami J. Tucker

Paul Dodwell

Lucille Doree

Karen M. Durbak

Jackie Eber

Michael F. Score

Harold and Edna Seemann

Richard and Ellen Seiden

A. Marilyn Sime, Ph.D., R.N.

Timothy Jay Smith

Dr. Judith A. Snyder

Lisa Spiekermann

Steven Brad Stacey

Nell V. Steele

Jo Ann Steggerda

Brenda M. Tolley

Clivia Torres-Lacend

Cheryl K. Turay

Ruby B. Van Rooyen

Kenneth and Mary J. Voertman

Jana R. and Stephen Wessels

Roger K. West

Margaret J. Whittle

Kevin Timothy Wilson

Gregory J. Winslow

Martha Wood

Robert P. Woodward

Charles and Marsha Woolley

Gloria Wren

Edward Wright

Evelyn Zafran

Susan K. Zeller

Gail M. Zimmerman

Seymour and Rebecca Lutto, in memory of their son Lawrence Lutto, $2 million, the largest bequest in Foundation history (See pg. 9 for their story.)

Anonymous

Barbara D. Collins

Catherine M. Cunningham

Jesse & Millie Fusfeld Family Trust

BEQUESTS

LEGACY SOCIETY

Hazel Grayson, in memory of her daughter Patricia J. Grayson

Mathilda A. Kamerman

Marian C. LaGodna

Thomas and Victoria Maguda

Eugene G. Maurer

Richard L. Elmendorf


Michael C. Finn, M.D.

Bruce and Susan Foat

Ruth I. Foerster

Carole and Marvin Frankel

Robert and Cynthia Galletly

Robert Ginsberg

Rich W. Good

Donald and Lesley Grilli

Bill and Mary Ann Grove

Louise K. Hawke

Mrs. Mary Beth Hedrick

Carol W. Henshaw

Jim Hergert

Lynn Hodges

Dr. Amy J. Holstein


Charles H. Jacobs

Betty Johnson

David W. Kapor

Diane and John Kazibut

Mara Kelly

Eric W. Kimble

William and Frances Klein

SaraLee and Barry Larner

Brian Larson

Patricia A. Laurie

Edward D. Lewis

Carl Wayne Littlejohn

Scott S. Lochridge

Charles Campbell Magee

Ellen Louise Magee

Mark and Jaclyn Marinovich

Craig and Irene McCall

Rebecca and John McCann

Sharon E. McCrae

Glennis McNeal

Kenneth A. Meersand

Linda Miller

Diane E. Moore

Marcy A. Morris

Mary L. Mullarkey

Chip Newton and Liz Smith

Robert J. Osterman

Ed and Laura Owens

Diane N. Paul

Harold and Harriet Phillips

Eileen Prouty

Diane Robinson

Sherri A. Rosen

Marie D. Roser

Irvin J. Roth

Barbara and Paul Sanders

Pamela B. Schultz

Harry Paulick

Marie R. Pitchford

Yuri Prizel

William Throckmorton Putnam III

Tessie Wolk

Phot

o co

urte

sy o

f Mar

k Sc

hlam


PRESIDENT’S COUNCIL

Elizabeth A. Abel, M.D.

William Abramovits, M.D.

Christine M. Adamick, M.D.

Donald J. Adler, D.O.

Andrew F. Alexis, M.D., M.P.H.

Laila Almeida, M.D.

Kenneth S. Alpern, M.D.

David J. Altman, M.D., Ph.D.

Lawrence L. Anderson, M.D.

Nancy J. Anderson, M.D.

Humberto C. Antunes

Peter J. Aronson, M.D.

Jerry Bagel, M.D.

Diane R. Baker, M.D.

Rodney S.W. Basler, M.D.

Eric W. Baum, M.D.

Vincent Peter Beltrani, Jr., M.D.

Paul R. Bergstresser, M.D.

Brian Berman, M.D., Ph.D.

J. Raymond Bernat, M.D.

Michael Bernhardt, M.D.

Neal Bhatia, M.D.

Joseph B. Bikowski, M.D.

Charles Birbara, M.D.

Andrew Blauvelt, M.D.

David Blum, M.D.

Erin E. Boh, M.D., Ph.D.

Mary Ruth Buchness, M.D.

Michael Bukhalo, M.D.

Daniel A. Buscaglia, D.O.

Jeffrey P. Callen, M.D.

Kristina Callis Duffin, M.D.

Charles Camisa, M.D.

Patrick Carney, M.D.

Carolina Mountain Dermatology

Daniel Carrasco, M.D.

Tamella B. Cassis, M.D.

Jennifer Clay Cather, M.D.

Robert L. Chappell, M.D.

May J. Chow, M.D.

David Clemons, M.D.

Missy M. Clifton, M.D.

Russell W. Cohen, M.D.

Steven R. Cohen, M.D., M.P.H.

Kevin D. Cooper, M.D.

Raymond L. Cornelison, Jr., M.D.

David J. Coynik, M.D.

Jeffrey Crowley, M.D.

Theodore Daly, M.D.

Kenneth Dawes, M.D.

Jim Del Rosso, D.O.

A. Damian Dhar, M.D.

N. Fred Eaglstein, D.O.

Joseph S. Eastern, M.D.

Craig A. Elmets, M.D.

Michelle Endicott, D.O.

John A. Erianne, M.D.

Colby C. Evans, M.D.

Lydia Evans, M.D.

John H. Exner, M.D.

Steven R. Feldman, M.D., Ph.D.

Neil A. Fenske, M.D.

A. Fernandez-Obregon, M.D.

David Fiorentino, M.D., Ph.D.

David P. Fivenson, M.D.

Mona Foad, M.D.

Michael Ford, M.D.

Joseph Francis Fowler, Jr., M.D.

Ellen H. Frankel, M.D.

Steven A. Franks, M.D.

Scott Fretzin, M.D.

Glenn H. Fuchs, M.D.

Loren S. Funt, M.D.

Bernard A. Gasch, M.D.

Joel M. Gelfand, M.D.

Brad P. Glick, D.O.

Bernard S. Goffe, M.D.

David J. Goldberg, M.D.

Michael T. Goldfarb, M.D.

Harry M. Goldin, M.D.

Roger S. Golomb, M.D.

Kenneth B. Gordon, M.D.

Alice Bendix Gottlieb, M.D., Ph.D.

Jennifer W. Gould, M.D.

Gloria F. Graham, M.D.

Richard D. Granstein, M.D.

Lawrence J. Green, M.D.

Harry L. Greenberg, M.D.

Joseph Greenberg, M.D.

Robert G. Greenberg, M.D.

Scott T. Guenthner, M.D.

Cynthia Guzzo, M.D.

Charles L. G. Halasz, M.D.

Tiffani K. Hamilton, M.D.

John G. Hancox, M.D.

Aubrey Chad Hartmann, M.D.

Sarah A. Haydel, M.D.

Stephen E. Helms, M.D.

David R. Hensley, M.D.

Warren R. Heymann, M.D.

Julie A. Hodge, M.D.

Deirdre Hooper, M.D.

Luciann L. Hruza, M.D.

Sylvia Hsu, M.D.

Charles Hudson, M.D.

Davide Iacobelli, M.D.

Francis W. Iacobellis, M.D.

Sarah C. Jackson, M.D.

J. Mark Jackson, M.D.

Robert L. Jackson, M.D.

Peter J. Jenkin, M.D.

Joseph L. Jorizzo, M.D.

Robert E. Kalb, M.D.

Susan E. Katz, M.D.

Leon Kircik, M.D.

John Y. M. Koo, M.D.

Neil Korman, M.D., Ph.D.

Craig A. Kraffert, M.D.

Cheryl Kramer

James M. Krell, M.D.

Indira Rao Krishnarao, M.D.

Gerald G. Krueger, M.D.

William V. Krug, M.D.

Sarah A. Kurts, PA-C

Michael A. Kurzman, M.D.

Richard Langley, M.D.

Stanton S. Lebouitz, M.D.

Mark G. Lebwohl, M.D.

Craig L. Leonardi, M.D.

Giulio A. Leone, M.D.

Jacob Levitt, M.D.

Ross S. Levy, M.D.

Gary D. Lichten, M.D.

Clive M. Liu, M.D.

Benjamin Lockshin, M.D.

Frederick A. Lupton III, M.D.

William Lynch, M.D.

Farah K. Malick, M.D.

Eugene Mandrea, M.D.

Linda Susan Marcus, M.D.

Barbara M. Mathes, M.D.

Robert T. Matheson, M.D.

Timothy D. Mattison, M.D.

Elizabeth I. McBurney, M.D.

Thomas S. McCormick, Ph.D.

Patrick S.J. McElgunn, M.D.

Philip J. Mease, M.D.

Alan M. Menter, M.D.

Lawrence S. Meyers, M.D.

Jami Lyn Miller, M.D.

Richard A. Miller, D.O.

Andrew J. Mitchell, M.D.

Craig Mohney, M.D.

Angela Yen Moore, M.D.

Warwick L. Morison, M.D.

Manuel R. Morman, M.D., Ph.D.

Mount Sinai School of Medicine, Department of Dermatology

George J. Murakawa, M.D., Ph.D.

John C. Murray, M.D.

Mark S. Nestor, M.D., Ph.D.

David S. Nieves, M.D.

Robert A. Norman, D.O., M.P.H.

Martin M. Okun, M.D.

Seth J. Orlow, M.D., Ph.D.

Patrick Ottuso, M.D.

Amy S. Paller, M.D.

Robert J. Pariser, M.D.

Jeffrey D. Pittis, M.D.

Justin Platzer, M.D.

Robert B. Posnick, M.D.

Steven A. Proper, M.D., M.P.H.

Ronald B. Prussick, M.D.

Abrar A. Qureshi, M.D.

John Karl Randall, M.D., R.Ph.

Oliver M. Reed, M.D.

Charles N. Reed, M.D.

Kathleen Remlinger, M.D.

Phoebe Rich, M.D.

Jennifer M. Ridge, M.D.

Darrell S. Rigel, M.D.

Christopher Ritchlin, M.D.

Douglas N. Robins, M.D.

Susan S. Roper, M.D.

Marti J. Rothe, M.D.

Beata L. Rydzik, M.D.

Neil Sadick, M.D.

Hans M. Sander, M.D.

Michael A. Scannon, M.D.

Robert F. Schwarze, D.O.

David C. Semler, M.D.

Kara Shah, M.D.

Kerry Shafran, M.D.

Patrick Shannon, M.D.

Mary E. Shepherd, M.D., Ph.D.

Jerome L. Shupack, M.D.

Michael T. Siegel, M.D.

David N. Silvers, M.D.

Robert A. Snyder, M.D.

Howard L. Sofen, M.D.

Mark Steele, NeoStrata Company

Linda Stein Gold, M.D.

Seth R. Stevens, M.D.

Lawrence M. Stokar, M.D.

Stephen P. Stone, M.D.

Timothy Jon Storer, M.D.

Bruce E. Strober, M.D., Ph.D.

Emil A. Tanghetti, M.D.

Artthapol Tanphaichitr, M.D.

Amy Forman Taub, M.D.

Craig F. Teller, M.D.

Ira H. Thorla, Jr., M.D.

Cynthia Tie, M.D.

Helen Mary Torok, M.D.

Eric S. Treiber, M.D.

Ruth K. Treiber, M.D.

James E. Turner, M.D., Ph.D.

Stephen K. Tyring, M.D., Ph.D.

Eugene J. Van Scott, M.D.

Abby S. Van Voorhees, M.D.

Panos Vasiloudes, M.D., Ph.D.

Allison Vidimos, M.D.

K. Dawn Vincent, M.D.

Paul Wallace, M.D.

Robert R. Walther, M.D.

Guy Webster, M.D., Ph.D.

Jeffrey M. Weinberg, M.D.

Gerald D. Weinstein, M.D.

Jonathan S. Weiss, M.D.

Stefan Weiss, M.D.

Schield M. Wikas, D.O.

Johnnie Woodson, M.D.

Paul S. Yamauchi, M.D., Ph.D.

Joseph J. Zaladonis, Jr., M.D.

Michael Zanolli, M.D.

Medical professionals who demonstrate their commitment to

the patient community through their membership.

MISSION: To find a cure for psoriasis and psoriatic arthritis and to eliminate their devastating effects through research, advocacy and education.

6600 SW 92nd Ave., Suite 300

Portland, OR 97223-7195

Telephone: 503.244.7404 | 800.723.9166 | Fax: 503.245.0626

Website: www.psoriasis.org | Email: [email protected]

TOP WALK TEAMS 2011-2012

PRESENTING SPONSOR

NATIONAL SPONSORS

Laub Weiss Team Carol Laub

Henschels Victors Jamie Henschel

Team 11,12,13 Challenge Kathryn Markham

Pop’s Dream Neal Henschel

Steph’s Striders Stephanie Gearhart

Rick’s Team Rick Seiden

Bender’s Helpers Dean Bender

Team Alyssa Alyssa Krafsur

Team Janssen Arlene Bitmansour

PSam Psays Pso What Sam Lichten

Refermat Smack Down Allison Refermat

Team JBI Priscilla Tavener

Savanna’s Priority 4 Psoriasis Savanna Swanson

Bender family Janice Bender

TEAM SAM Sam Weinbaum

Beth’s Buddies Beth/David Geduld

Galderma Laboratories David Scriven

University of Utah Dermatology Kristina Duffin

Team Virtual Chip Newton

Team Cardine Corey Cardine

Pso Jeffrey Jeffrey Henschel

American Airlines Flight Crew

Gabba-goo Crew

Itchin’ to Walk

Walkers & Talkers

Team Hannah Banana

UCSF Psoriasis Center

Team Cohen

UPenn Dermatology

Team Amgen LA

Ron Grau

Team K

PSOul PSOlution

Finks

Cross Country Aches and Pflakes

Nicky’s Patch

Soles for Psoriasis

Team Melanie

Bellaire Dermatology Associates

PAMF PASIs

Abbott Team

Team Baker

Walgreens Team SLC

Team Jojo

Hunnibell-Moroney

Team DAVEN

Raising Money for a Cure!

Walk with Erin

Team Fayetteville

phillywalkfriends

Team Menter

Joint Relief

UCLA Derm Team

Team McKenna

Team Wisse

Abbott Immunology Chicago

Neutrogena Los Angeles

TOP LOCAL SPONSORS Aventura Mall South Florida

Altman Dermatology Associates Chicago

Drinker Biddle & Reath Washington, D.C.

Infinite Healthcare Partners LLC South Florida

OTIS San Diego

Thank you to our Walk to Cure Psoriasis Corporate Sponsors:

JULY 1, 2011–JUNE 30, 2012

2012 ANNUAL REPORT ROAD TO A CURE

Documents

Transcript of 2012 ANNUAL REPORT ROAD TO A CURE